NYSEAMERICAN:LCTX

Lineage Cell Therapeutics - LCTX Stock Forecast, Price & News

$1.13

-0.02 (-1.74%)

(As of 09/30/2022 12:00 AM ET)

Add

Compare

Today's Range: $1.13
▼
$1.18
50-Day Range: N/A
52-Week Range: $1.10
▼
$2.71

Volume: 184,655 shs
Average Volume: 261,487 shs
Market Capitalization: $191.83 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $6.00

Lineage Cell Therapeutics MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 431.0% Upside
$6.00 Price Target
Short Interest: Healthy
2.62% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.75 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
Lineage Cell Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $6.00, Lineage Cell Therapeutics has a forecasted upside of 431.0% from its current price of $1.13.
Amount of Analyst Coverage
Lineage Cell Therapeutics has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
2.62% of the outstanding shares of Lineage Cell Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Lineage Cell Therapeutics has a short interest ratio ("days to cover") of 6.6.
Change versus previous month
Short interest in Lineage Cell Therapeutics has recently decreased by 2.84%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Lineage Cell Therapeutics does not currently pay a dividend.
Dividend Growth
Lineage Cell Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for LCTX.

0.6

News and Social Media Coverage

Search Interest
5 people have searched for LCTX on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Lineage Cell Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -88% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Lineage Cell Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
26.70% of the stock of Lineage Cell Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 38.29% of the stock of Lineage Cell Therapeutics is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Lineage Cell Therapeutics are expected to remain at ($0.16) per share in the coming year.
Price to Earnings Ratio vs. the Market
The P/E ratio of Lineage Cell Therapeutics is -3.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Lineage Cell Therapeutics is -3.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Lineage Cell Therapeutics has a P/B Ratio of 2.09. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Stock

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers Renevia, a facial aesthetics product. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.

Receive LCTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lineage Cell Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

LCTX Stock News Headlines

September 22, 2022 | seekingalpha.com

LCTX Lineage Cell Therapeutics, Inc.

August 15, 2022 | finance.yahoo.com

Lineage to Present at H.C. Wainwright & Co. 2nd Annual Virtual Ophthalmology Conference

August 12, 2022 | fool.com

Lineage Cell Therapeutics, Inc. (LCTX) Q2 2022 Earnings Call Transcript

August 11, 2022 | msn.com

Recap: Lineage Cell Therapeutics Q2 Earnings

August 4, 2022 | finance.yahoo.com

Lineage Cell Therapeutics to Report Second Quarter 2022 Financial Results and Provide Business Update on August 11, 2022

June 2, 2022 | finance.yahoo.com

Lineage Broadens Collaboration With Advanced BioMatrix for HyStem® Cell Drug Delivery Technology

May 16, 2022 | finance.yahoo.com

Lineage Cell Therapeutics, Inc. (LCTX) Q1 2022 Earnings Call Transcript

May 13, 2022 | seekingalpha.com

Lineage Cell Therapeutics, Inc. (LCTX) CEO Brian Culley on Q1 2022 Results - Earning Calls Transcript

May 11, 2022 | benzinga.com

Earnings Preview: Lineage Cell Therapeutics

May 5, 2022 | finance.yahoo.com

Lineage Cell Therapeutics to Report First Quarter 2022 Financial Results and Provide Business Update on May 12, 2022

May 4, 2022 | seekingalpha.com

Lineage Cell buoyed by phase 1/2a results for macular degeneration therapy

May 3, 2022 | finance.yahoo.com

RG6501 (OpRegen®) Phase 1/2a Clinical Results Support the Potential for OpRegen to Slow, Stop or Reverse Disease Progression in Geographic Atrophy Secondary to Age-Related Macular Degeneration

April 26, 2022 | finance.yahoo.com

Lineage to Present at B. Riley Securities 2022 Neuro & Ophthalmology Virtual Investor Conference on April 27, 2022

April 25, 2022 | seekingalpha.com

Lineage stock rises after announcing cell therapy program to treat vision loss

April 13, 2022 | finance.yahoo.com

Lineage and Cancer Research UK Announce Completion of Patient Enrollment in Phase 1 Clinical Study of VAC2 for the Treatment of Non-small Cell Lung Cancer

April 11, 2022 | finance.yahoo.com

Lineage to Present at the NobleCon18 Investor Conference on April 20, 2022

March 24, 2022 | finance.yahoo.com

Lineage to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC on March 28, 2022

March 21, 2022 | finance.yahoo.com

YmAbs Therapeutics, Inc. (YMAB) Soars 11.3%: Is Further Upside Left in the Stock?

March 21, 2022 | finance.yahoo.com

Lineage Announces Pipeline Expansion to Include Auditory Neuronal Cell Therapy for Treatment of Hearing Loss

March 14, 2022 | benzinga.com

Lineage Cell Therapeutics's Return On Capital Employed Insights

March 14, 2022 | finance.yahoo.com

RG6501 (OpRegen®) Full Phase 1/2a Results to Be Featured at 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Presentation by Allen C. Ho, M.D., FACS

March 10, 2022 | finance.yahoo.com

Lineage Cell (LCTX) Reports Q4 Loss

March 10, 2022 | finance.yahoo.com

Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

March 9, 2022 | benzinga.com

Lineage Cell Therapeutics's Earnings: A Preview

March 1, 2022 | finance.yahoo.com

Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Business Update on March 10, 2022

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive LCTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lineage Cell Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

LCTX Company Calendar

Last Earnings: 11/10/2021
Today: 10/01/2022
Next Earnings (Estimated): 11/08/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSEAMERICAN
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NYSEAMERICAN:LCTX
CUSIP: N/A
CIK: N/A
Web: www.lineagecell.com
Phone: (510) 521-3390
Fax: 510-521-3389
Employees: 57
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $6.00
High Stock Price Forecast: $8.00
Low Stock Price Forecast: $4.00
Forecasted Upside/Downside: +431.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.30)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-43,020,000.00
Net Margins: -382.15%
Pretax Margin: -382.59%
Return on Equity: -32.03%
Return on Assets: -20.61%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.95
Quick Ratio: 2.95

Sales & Book Value

Annual Sales: $4.34 million
Price / Sales: 44.20
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.54 per share
Price / Book: 2.09

Miscellaneous

Outstanding Shares: 169,760,000
Free Float: 124,430,000
Market Cap: $191.83 million
Optionable: Optionable
Beta: 1.59

Key Executives

Mr. Brian M. Culley M.A. (Age 51)
M.B.A., CEO, Pres, Interim CFO, Principal Financial Officer & Director
Comp: $913.5k

Mr. George A. Samuel III (Age 41)
J.D., Gen. Counsel & Company Sec.
Comp: $175.63k

Ms. Alexandra Hernandez
Interim Principal Accounting Officer, Sr. Director of Fin. & Controller

Ioana C. Hone
Director of Investor Relations

Dr. Gary S. Hogge D.V.M. (Age 53)
Dvm, Ms, Ph.D., Sr. VP of Clinical & Medical Affairs

Ms. Brandi L. Roberts CPA (Age 48)
M.B.A., Consultant

Mr. William Annett (Age 68)
Pres & CEO of OncoCyte Corp.

Dr. Rami Skaliter (Age 64)
Chief Exec. Officer of Cell Cure Neurosciences Ltd.

Dr. Harold D. Waitz (Age 80)
VP of Regulatory Affairs & Quality Control

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

LCTX Stock - Frequently Asked Questions

Should I buy or sell Lineage Cell Therapeutics stock right now?: 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lineage Cell Therapeutics in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" LCTX shares.
View LCTX analyst ratings or view top-rated stocks.
What is Lineage Cell Therapeutics' stock price forecast for 2022?: 5 Wall Street analysts have issued 12 month price objectives for Lineage Cell Therapeutics' shares. Their LCTX share price forecasts range from $4.00 to $8.00. On average, they expect the company's share price to reach $6.00 in the next twelve months. This suggests a possible upside of 431.0% from the stock's current price.
View analysts price targets for LCTX or view top-rated stocks among Wall Street analysts.
How have LCTX shares performed in 2022?: Lineage Cell Therapeutics' stock was trading at $1.78 at the beginning of the year. Since then, LCTX shares have decreased by 36.5% and is now trading at $1.13.
View the best growth stocks for 2022 here.
Are investors shorting Lineage Cell Therapeutics?: Lineage Cell Therapeutics saw a decrease in short interest in August. As of August 15th, there was short interest totaling 4,480,000 shares, a decrease of 7.4% from the July 31st total of 4,840,000 shares. Based on an average trading volume of 839,700 shares, the short-interest ratio is presently 5.3 days.
View Lineage Cell Therapeutics' Short Interest.
When is Lineage Cell Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our LCTX earnings forecast.

How were Lineage Cell Therapeutics' earnings last quarter?: Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) issued its earnings results on Wednesday, November, 10th. The company reported ($0.05) EPS for the quarter, meeting the consensus estimate of ($0.05). The firm earned $2.27 million during the quarter, compared to analysts' expectations of $0.56 million. Lineage Cell Therapeutics had a negative net margin of 382.15% and a negative trailing twelve-month return on equity of 32.03%.
What other stocks do shareholders of Lineage Cell Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Lineage Cell Therapeutics investors own include Matinas BioPharma (MTNB), Bionano Genomics (BNGO), Gran Tierra Energy (GTE), ADMA Biologics (ADMA), Novan (NOVN), Pennsylvania Real Estate Investment Trust (PEI), CNBX Pharmaceuticals (CNBX), Enerplus (ERF), KushCo (KSHB) and Zosano Pharma (ZSAN).
What is Lineage Cell Therapeutics' stock symbol?: Lineage Cell Therapeutics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "LCTX."
How do I buy shares of Lineage Cell Therapeutics?: Shares of LCTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Lineage Cell Therapeutics' stock price today?: One share of LCTX stock can currently be purchased for approximately $1.13.
How much money does Lineage Cell Therapeutics make?: Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) has a market capitalization of $191.83 million and generates $4.34 million in revenue each year. The company earns $-43,020,000.00 in net income (profit) each year or ($0.30) on an earnings per share basis.
How can I contact Lineage Cell Therapeutics?: Lineage Cell Therapeutics' mailing address is 2173 SALK AVENUE SUITE 200, CARLSBAD CA, 92008. The official website for the company is www.lineagecell.com. The company can be reached via phone at (510) 521-3390, via email at ir@lineagecell.com, or via fax at 510-521-3389.

This page (NYSEAMERICAN:LCTX) was last updated on 10/1/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Lineage Cell Therapeutics - LCTX Stock Forecast, Price & News

Lineage Cell Therapeutics MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month